Exact sciences corporation stock.

Shares Held % O/S Share Change Filing Date; The Vanguard Group, Inc. 17,175: 9.52: 164: 06/30/2023: JPMorgan Investment Management, Inc. 12,307: 6.82: 878: 06/30/2023Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently up 1.28% so far this month. During the month of April, Exact Sciences Corp’s stock price has reached a high of $68.77 and a low of $63.37. Over the last year, Exact Sciences Corp has hit prices as high as $72.19 and as low as $29.27. Year to date, Exact ...Discover historical prices for EXAS stock on Yahoo Finance. View daily, weekly or monthly format back to when Exact Sciences Corporation stock was issued.Exact Sciences completed its $2.8 billion cash-and-stock merger with Genomic Health in November 2019, according to a press release. Through the deal, Genomic Health became a subsidiary of Exact ...Shares of Exact Sciences (NASDAQ:EXAS) were soaring 9.8% higher as of 3:38 p.m. EDT on Thursday. The company announced on Wednesday that new data for its ...

Business intelligence is what S&P ratings are all about. This global corporation provides credit ratings on investments, including bonds and the stock market. Before you can understand what a good rating is, it helps to understand the origi...Shares Held % O/S Share Change Filing Date; The Vanguard Group, Inc. 17,175: 9.52: 164: 06/30/2023: JPMorgan Investment Management, Inc. 12,307: 6.82: 878: 06/30/2023 Sociology, which is the study of human social behavior, can have a quantifiable effect on the application of economics in many ways. Stock market prices, for example, are often influenced much more by the perceptions of investors and shareh...

According to our research, EXAS stock is a good long-term investment. EXAS share price has been in a bull cycle for the past year. Exact Sciences Corporation stock trend is positive .About EXAS. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

MADISON, Wis., April 10, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2023 financial results after the close of the U.S. financial markets on May 9, 2023.Exact Sciences' revenue has grown rapidly in the past five years, but the bottom line hasn't made much progress. Cologuard 2.0 should help the company's top line maintain its momentum. Exact ...Our mission at Exact Sciences is to eradicate cancer and the suffering it causes — through tests that help prevent it, detection that finds it earlier, and guidance for its successful treatment. Our Tests Exact Sciences Corp. is a molecular diagnostics company specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer, in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer. Since then Exact Sciences has grown its product portfolio to ... Nov 1, 2023 · Exact Sciences Corp (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, announced on November 1, 2023, that the company generated revenue of $628.3 million for the third ...

The stock of Exact Sciences Corp. (EXAS) has gone down by -0.12% for the week, with a 10.16% rise in the past month and a -21.44% drop in the past quarter. The volatility ratio for the week is 3.39%, and the volatility levels for the past 30 days are 4.51% for EXAS. The simple moving average for the last 20 days is 2.04% for EXAS stock, with …

Oncotype DX ® Test Recognized as the 'Preferred' and Only Multigene Test to Predict Chemotherapy Benefit in Node-positive Early-stage Breast Cancer. Update based on first results from the independent RxPONDER study presented at the 2020 San Antonio Breast Cancer Symposium 1. Madison, Wis., March 31, 2021 - Exact Sciences today …

MADISON, Wis., Aug. 2, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $521.6 million for the second quarter ended June 30, 2022, compared to $434.8 million for the same period of 2021.Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal ...Exact Sciences Corporation (NASDAQ:EXAS) Q4 2022 Earnings Conference Call February 21, 2023 5:00 PM ETCompany Participants. Megan Jones - Investor Relations. Kevin Conroy - Chairman and Chief ...Adjusted EBITDA for the three and six months ended June 30, 2021 has been updated accordingly for comparative purposes. Of the $64.5 million and $60.8 million incurred for the three months ended June 30, 2022 and 2021, $56.4 million and $53.9 million is related to stock-based compensation, respectively, and $8.1 million and $6.9 million is ...Stock Information · Financial Information · SEC Filings · Quarterly Results ... © Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI 53719. Powered By ...MADISON, Wis., Feb. 23, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23, 2023 it entered into a privately negotiated exchange and purchase agreement (the "Agreement") with a holder of certain of the Company's 0.3750% Convertible Senior Notes due 2027 (the "Existing 2027 ...Nov 17, 2023 · Get the latest Exact Sciences Corporation (EXAS) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.

16 brokers have issued twelve-month price targets for Exact Sciences' stock. Their EXAS share price targets range from $73.00 to $130.00. On average, they expect the company's share price to reach $96.56 in the next year. This suggests a possible upside of 44.1% from the stock's current price. View analysts price targets for EXAS or view top ...Exact Sciences (EXAS) Stock Price & Analysis ; Previous Close$66.3 ; Volume2.13M ; Average Volume (3M)1.45M ; Market Cap. $11.99B ; Enterprise Value$13.82B.On May 17, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $78.63 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of ...26-Apr-2022 ... MADISON, Wis., April 26, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that ...Shares of Exact Sciences ( EXAS 0.93%) stormed higher by 16.5% over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain ...Exact Sciences is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Ultragenyx (RARE), a stock from the same industry, has gained 6.7%.Our pipeline team is responsible for advancing our future tests and developing life-changing cancer diagnostics to help patients throughout the course of their diagnosis and treatment.

EXACT Sciences News: This is the News-site for the company EXACT Sciences on Markets Insider Indices Commodities Currencies Stocks

"Exact Sciences Corporation (NASDAQ:EXAS) is a cancer diagnostics company whose flagship product is Cologuard, a stool-based screening test for colon cancer. The stock declined because financial ...About Exact Sciences Corp. ... Stock-based compensation including the incremental fair value of assumed stock awards and accelerated vesting from post-acquisition qualified termination events was $4.2 million and $8.2 million for the three and nine months ended September 30, 2020.EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is ...About EXAS. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.Oct 19, 2023 · "Exact Sciences Corporation (NASDAQ:EXAS) is a cancer diagnostics company whose flagship product is Cologuard, a stool-based screening test for colon cancer. The stock declined because financial ... MADISON, Wis., April 26, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that the company generated revenue of $486.6 million for the first quarter ended March 31, 2022, compared to $402.1 million for the same period of 2021.

EXAS is the ticker symbol for Exact Sciences Corporation, a company that provides cancer screening and diagnostic test products. The stock price, news, quote, history and performance outlook of EXAS are shown on Yahoo Finance. See the latest earnings …

Determining the value of old vinyl records isn’t an exact science, according to Rare Records. A variety of factors go into determining the value of a record, and these factors are what give some vinyl albums a high value while others don’t ...

Stock analysis for Exact Sciences Corp (EXAS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile."Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that …Negative. Nikkei 225. 33,451.83. +0.29%. Positive. Source: LSEG - data delayed by at least 15 minutes. Get Exact Sciences Corp (EXAS.A) real-time stock quotes, news, price and financial ...Nov 30, 2022 · Exact Sciences Corp’s stock is NA in 2023, NA in the previous five trading days and up 56.77% in the past year. Currently, Exact Sciences Corp does not have a price-earnings ratio. Exact Sciences Corp’s trailing 12-month revenue is $2.4 billion with a -11.7% net profit margin. Year-over-year quarterly sales growth most recently was 20.1%. Jan 12, 2023 · Exact Sciences' valuation has been plummeting. In 2022, shares of Exact Sciences fell 36%, underperforming the S&P 500, which declined by 19%. Exact Sciences isn't near its 52-week low of $29.27 ... Nov 9, 2023 · Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently down 3.17% so far this month. During the month of November, Exact Sciences Corp’s stock price has reached a high of $68.02 and a low of $59.51. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $39.90. Year to date, Exact ... MADISON, Wis., April 12, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it will present new data highlighting the company's novel technology and approaches to early cancer detection at the American Association for Cancer Research® (AACR) Annual …Ordinary share capital refers to shares that are issued by a company that allow shareholders voting rights within a corporation. Ordinary shareholders may also receive dividends. Ordinary shares are also referred to as common stocks.About EXAS. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS ), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of ...

Jan 12, 2023 · Exact Sciences' valuation has been plummeting. In 2022, shares of Exact Sciences fell 36%, underperforming the S&P 500, which declined by 19%. Exact Sciences isn't near its 52-week low of $29.27 ... May 9, 2023 · MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 million for the first quarter ended March 31, 2023, compared to $486.6 million for the same period of 2022. Globally, the cancer diagnostics market was worth $172.3 billion in 2022, according to analysts from Grand View Research. And by 2030, they project that will rise to $293.5 billion, averaging a ...Exact Sciences Corporation issued to certain of the selling stockholders of Paradigm an aggregate of 381,047 shares of common stock as initial merger consideration for their ownership in Paradigm. In addition, Exact Sciences Corporation withheld 45,338 shares of common stock payable as additional merger consideration to such selling ...Instagram:https://instagram. top movers in stock marketnasdaq omh newslucid stoctop cryptocurrency brokers Imperialism exists today, but not in the exact form practiced during the Roman Empire or the British Empire. Capitalism is a major driver of modern imperialism as corporations, such as banks and oil companies, expand globally to generate mo...Exact Sciences Corp’s stock is NA in 2023, NA in the previous five trading days and up 56.77% in the past year. Currently, Exact Sciences Corp does not have a price-earnings ratio. Exact Sciences Corp’s trailing 12-month revenue is $2.4 billion with a -11.7% net profit margin. Year-over-year quarterly sales growth most recently was 20.1%. how to know if a quarter is worth moneyinsurance for water and sewer lines Jul 19, 2023 · Financial Performance. Exact Sciences reported Q1 2023 results with total revenue of $602.5M (up 24% from 2022). Core revenue increased by 33% to $597.8M, led by a 45% surge in screening revenue ... Exact Sciences Corporation‘s (EXAS Quick Quote EXAS - Free Report) shares have surged 35.4% year to date against the industry’s decline of 21.2%. The Medical sector has dropped 8.1% in the ... amprius tech stock 03-Nov-2023 ... everyone excited? Whoo. The stock is up. That's good. ... Exact Sciences and chairman and CEO Kevin Conroy. ... sciences commitment to earlier ...Buy Exact Sciences Corporation Shares from India at $67.03 (0 Commission) today. Start investing in Exact Sciences Corporation stocks from India now with fractional investing only on INDmoneyapp